<DOC>
	<DOCNO>NCT02526017</DOCNO>
	<brief_summary>This phase 1a/b single-arm , open-label study evaluate safety , tolerability , PK , clinical benefit FPA008 combination nivolumab patient select advanced cancer .</brief_summary>
	<brief_title>Study FPA008 Combination With Nivolumab Patients With Selected Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Patients must least one measurable lesion baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) per RECIST v1.1 criterion . Patients must progressive disease , , refuse , appropriate approve therapy tumor type . Understand sign IRB/IECapproved ICF prior studyspecific evaluation ECOG performance status 0 1 Willing able comply study procedure Current history clinically significant muscle disorder ( e.g. , myositis ) , recent unresolved muscle injury , condition know elevate serum CK level Decreased cardiac function NYHA &gt; Class 2 Uncontrolled significant heart disorder unstable angina Significant abnormalities ECG screening . QTcF &gt; 450 msec male &gt; 470 msec female screen History antidrug antibody , severe allergic , anaphylactic , infusionrelated reaction previous biologic agent Positive test latent tuberculosis ( TB ) screening ( Quantiferon test ) evidence active TB Patients abnormal serum chemistry value , opinion Investigator consider clinically significant , exclude study Lack peripheral venous central venous access condition would interfere drug administration collection study sample Any uncontrolled medical condition psychiatric disorder , opinion Investigator , would pose risk patient safety interfere study participation interpretation individual patient result Pregnant breastfeed Current unresolved infection history chronic , active , clinically significant infection ( viral , bacterial , fungal , ) , opinion Investigator , would preclude patient exposure biologic agent pose risk patient safety Prior exposure CSF1R pathway inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>